104 results about "Submucosa" patented technology

Medical devices and methods are designed to bias stretch receptors in the stomach wall of a patient to treat obesity. Biasing of the stretch receptors by pre-stretching induces an early sensation of satiety, causing the patient to consume less food. Biasing of the stretch receptors can be achieved by the placement of bulking devices within the wall of the stomach, e.g., in the mucosa, submucosa or muscle layer. The bulking devices may be expandable and, in some embodiments, may take the form of a hydrogel prosthesis that expands following implantation in a wall of the stomach.

To provide a medical device and a method both of which can suitably embolize a bronchus in a target part by embolizing the bronchus with (at least a part of) a living tissue during surgical treatment of lung emphysema. For example, an injection material is injected into a submucosa by the use of a syringe, and in the injected part, a swelling swollen into the internal cavity of the bronchus is formed to tightly seal the living tissue of the bronchus or a bronchiole, thereby embolizing a target bronchus.

A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed.

The invention relates to a method for preparing a biomaterial of acellular small intestinal submucosa, which comprises the steps of preposition treatment, acellular treatment, enzyme treatment, preparations of membranous products and particle products. Compared with the prior art, the biomaterial has higher bioactivity and biocompatibility, no obvious immune rejection and no toxic effect on cells; besides, the biomaterial has a certain mechanical strength and toughness, and variable shape, size and thickness, thereby being convenient for clinical suturing and fixing. At the same time, the preparation method has the advantages of unlimited raw material source, cell-free residues, no ethical issues and being capable of effectively inactivating virus. The prepared products are applicable to the biomedical engineering fields, such as repairing defections of body tissue, serving as tissue filling materials, repairing facial depression deformity, serving as tissue reinforcements to replace fascia, repairing membranous defections and malnourished and infected surfaces of wound, serving as materials for biodegradable stents, and serving as injectable filling materials.

Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.

A small intestine submucosa mesh is adapted for use in surgical abdominal closure routines. The submucosa mesh is incorporated into the normal surgical protocol for abdominal closure procedures. The submucosa mesh is applied to the abdominal incision area and maintains and enhances the stability and integrity of the abdominal wall closure, thereby preventing the onset or occurrence of incisional hernias. The submucosa mesh can also be applied to surgical closure procedures involving treatment of a hernia defect, such as an incisional hernia or other non-incisional hernia. The submucosa construct can also be adapted for use as a suturing component or bioretention suture. The submucosa construct can be adapted for use as part of a surgical strategy to facilitate wound healing, regeneration, reconstruction, and replacement of anatomical structures, such as tissues and organs.

A method for surgical repair of damaged or diseased head and neck tissues is described. In one aspect of the invention tissue graft constructs comprising vertebrate submucosa or vertebrate basement membrane materials are used to repair and promote growth of endogenous vocal cord tissue.

A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and / or in a patient.

A composition comprising enzymatically digested submucosa of a warm-blooded vertebrate and a method of making that composition is described. More particularly the submucosa is enzymatically digested and gelled to form a shape retaining gel matrix suitable for inducing cell proliferation and growth both in vivo and in vitro.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and / or in a patient.

A treatment instrument for an endoscope is provided that is suitable for cutting submucosa in endoscopic submucosal dissection. The treatment instrument for an endoscope includes a treatment portion having a cutting unit at a tip of an insertion portion that is to be inserted into the body. The main unit of the treatment portion is formed in a sawtooth shape having a peak portion and a valley portion. An electrode plate serving as the cutting unit is provided in the valley portion.

Described are modified submucosa and other extracellular matrix materials incorporating an amount of bound, exogenous fibronectin. Further described are such materials also having an amount of exogenous heparin bound to the exogenous fibronectin, and also potentially an amount of an exogenous bioactive material, such as a growth factor, bound to the exogenous heparin. Such materials may be used in methods for the treatment of wounds in patients.

A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and / or in a patient.

The invention involves a submucosa tissue that has the capability of being shape formed or shape configured. The submucosa involves a purified form of submucosa tissue. Optionally, the submucosa can be packaged in such a manner to permit sterility or maintain sterility of the submucosa.

Embodiments of the invention are directed to a method of excising tissue including injecting fluid into the submucosa to raise targeted tissue. A first electrode is positioned below the targeted tissue within the injected fluid and a second electrode is positioned adjacent a surface of the raised targeted tissue opposite the first electrode. Electrical current is applied between the first and second electrodes and the targeted tissue is excised with the second electrode.

Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).

A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed.

Methods for maintaining patency in a bronchus of a patient are presented. A catheter is positioned within the bronchus. A target region of one or more of a bronchial wall, submucosa, media, and adventitia is punctured at or adjacent a location of a debulked bronchial carcinoma with an injection needle disposed on a distal end of the catheter. Such puncturing is achieved by expanding a balloon disposed on the distal end of the catheter. The balloon is comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. Through the injection needle, an amount of cytotoxic, cytostatic, or anti-neoplastic agent is delivered to the target region. The delivered amount is effective to limit by a therapeutically beneficial amount recurrent bronchial occlusion due to recurrence of the bronchial carcinoma.

Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients.

The invention discloses an application of the reagent for detecting clostridium symbiosum in preparing an early colorectal cancer diagnostic kit. According to the diagnostic kit, DNA of bacteria in excrement is extracted and a quantitative polymerase chain reaction is conducted so that the feature of relative abundance of the clostridium symbiosum can be acquired, and diagnosis of early colorectal cancers (limited to the colon cancer and the rectal cancer of submucosa) is conducted with the feature as a basis. Compared with noninvasive colorectal cancer screening methods applied to clinics at present and applied for a patent, the regent is completely noninvasive, operation is relatively easy and low in price, the colorectal cancers can be predicted more accurately, and the area under curve (AUC value) of an ROC curve is 0.70 or above.

Systems, devices, and methods for maintaining patency in a bronchus of a patient are presented. A catheter is positioned within the bronchus. A target region of one or more of a bronchial wall, submucosa, media, and adventitia is punctured with an injection needle disposed on a distal end of the catheter. Such puncturing is achieved by expanding a balloon disposed on the distal end of the catheter. The balloon may be comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. Through the injection needle, an amount of one or more crosslinking agents is delivered to the target region. The delivered amount is effective to provide structural support for the bronchial wall, substituting for the bronchial cartilage thereby treating bronchomalacia.

The invention discloses a traditional Chinese medicinal enema for treating chronic colitis. According to the traditional Chinese medicinal science, the pathogenesis of chronic colitis is mainly due to syndromes of dampness-heat due to spleen deficiency and qi depression to blood stasis, especially develops in colonic mucosa and submucosa inflammation and ulcer changes, and is characterized by stomachache, diarrhea, mucous bloody stool and tenesmus in clinic. Therefore, traditional Chinese medicines, which have effects of clearing heat, drying damp, diminishing swelling, promoting granulation,removing pattogenic heat from the blood and toxic material from the body, relieving diarrhea, diminishing inflammation, resolving tetany and relieving pain, including traditional Chinese medicinal Swamp Mahogany Leaf, champion dutchmanspipe root, mongolian oak bark, Scutellaria baicalensis, cortex fraxini, Cape jasmine, Rhizoma Atractylodis Macrocephalae, licorice root, Codonopsis pilosula, cortex albiziae, fruits of Litsea rubescens, cortex cinnamomi and hurricane lamp, are selected to be made into the enema. Through clinical tests of our public health centre, the total effective rate of theenema reaches 96.3% and it is obviously better than a control group. In addition, patients have no adverse reaction after taking the medicine. Therefore, the medicine is worth of clinical popularization and application.

A collagenous biomaterial medical device comprising a molded sponge material formed from comminuted submucosa fragments that have not been cross-linked with a cross-linking agent, wherein said submucosa has at least one biotropic agent, and wherein said biotropic agent is a growth factor is disclosed.

Mucositis is the result of a complex process of interactive biologic phenomena that take place in both the epitelium and the submucosa, often leading to severe pain and increased risk of dangerous syste f48 mic infections. Mucositis is often a side effect during chemotherapy and radiation therapy. The benzamidine derivatives herein described are particularly effective for treating and preventing mucositis since they are acting simultaneously at the several phases that characterize this disease. Data supplied from the esp@cenet database

An endoscope device (1), which comprises a light source (4), an endoscope (3), a processor (7) and a viewing monitor (5). The light source (4) switches the illumination light from an excitation light (EX) for exciting a connective tissue in the submucosa of a tissue within a body cavity to a narrowband light (NBa) that is absorbed by a blood vessel (64) running through the submucosa (62) or muscularis propria (63) and a narrowband light (NBb) that is absorbed by a substance topically injected into the submucosa (62). The processor (7) generates multiple image signals, said image signals having been obtained by taking images with CCD2 of the endoscope (3), and the viewing monitor (5) synthesizes and displays multiple images.

The invention discloses a biological sponge based on the acellular small intestinal submucosa and a preparation method thereof. The preparation method comprises the steps of preparing the acellular porcine small intestinal submucosa, pepsin enzymatic hydrolysis, washing, lyophilization, pulverization and cross-linking. According to the preparation method, the porcine small intestinal submucosa istaken as a source; after the decellularization treatment, the immunological rejection is extremely small. At the same time, the cross-linking treatment is carried out by using a non-toxic cross-linking agent to ensure the biosafety of the obtained product. The product can be used not only for wound repair, but also as an excellent tissue engineering skin scaffold material. The product is sufficient in source, safe and reliable, cheap and easy to obtain. The composition and structure are similar to the humans. No ethical problems exist, and scale industrial preparation can be facilitated.

The invention relates to a uterine cavity implant as well as a preparation method and application thereof. The uterine cavity implant is characterized by having a bagged structure. The uterine cavity implant comprises a substrate material of animal small intestine submucosa subjected to decellularization treatment. An implantable medical device for preventing and treating intrauterine adhesion comprises a biological tissue substrate material. The present decellularization technology for a biological repairing material is improved; compared with the present product, the biological tissue substrate material provided by the invention has the advantages of lower DNA residual quantity, lower immunogenicity, higher anti-infection capacity and higher repairing capacity; and the uterine cavity implant is beneficial to the recovering of tissues, such as, uterine cavity base layer, submucosa and mucous layer. Besides, the invention prepares the biological repairing material into the uterine cavity built-in structure which is used for isolating wound surfaces, repairing uterine cavity tissues and reducing scar forming, so that the intrauterine adhesion problem is solved, and the accordingly generated sterility problem also can be solved.

The invention discloses a traditional Chinese medicine naristillae for treating migraine. Traditional Chinese medical science considers that migraine is caused by external infection of six evils, infection of bump top and interference of lucid yang or improper diet, causes internal injury of spleen and kidney, and causes viscera disorder, qi and blood disorder and obstruction of meridians. Therefore, in the invention, traditional Chinese medicines such as flower bud of lily magnolia, radix angelicae, fructus viticis, corydalis tuber, pinellia cordata, ligusticum sinense, tuber fleeceflower stem, fructus piperis longi and borneol for dredging qi and dispelling wind and removing obstruction in the meridians are selected to prepare the naristillae. Clinical experiments in our hospital show that the total effective rate achieves 97.5 percent which is obviously better than that of a control group, and the time for headache remission is shorter than that of the control group. Clinical observation shows that treating migraine using the naristillae sufficiently utilizes the characteristic that the nasal cavity submucosa has abundant blood capillary and is poriferous and the advantage that medicine easily penetrates into blood and issue. The traditional Chinese medicine naristillae has the advantages of high curative effect, low dosage, convenience in use, no adverse reaction and the like.